breast cancer

[Cancer] The authors evaluate the use of cyclin-dependent kinase 4/6 inhibitors in the adjuvant setting based on the continued high rate of relapse in patients with node-positive, hormone receptor-positive breast cancer.

[Novartis Pharma AG (Globe Newswire, Inc.)] Novartis announced updated median overall survival (OS) results for Kisqali® in combination with fulvestrant in postmenopausal women with HR+/HER2- metastatic breast cancer. This combination demonstrated a clinically relevant OS benefit of more than a year compared with fulvestrant alone.

[Cannabics Pharmaceuticals, Inc. (PR Newswire, Inc.)] Cannabics Pharmaceuticals, Inc. announced the launching of a new research program for the development of a breast cancer antitumor targeting medicine following the successful completion of a series of preclinical experiments.

[Damon Runyon Cancer Research Foundation] (Peter) Geon Kim, MD, with mentor Benjamin L. Ebert, MD, PhD, at the Dana-Farber Cancer Institute, was one of five recipients of the 2021 Damon Runyon Physician-Scientist Training Award. Dr. Kim's research may provide insight into various inflammatory conditions associated with clonal hematopoiesis and potentially elucidate how clonal hematopoiesis progresses into blood cancer.

[Cell Death & Disease] Researchers analyzed colonic tissue samples from patients with ulcerative colitis (UC) and constructed specific intestinal epithelial phenazine biosynthesis-like domain-containing protein (PBLD)-deficient mice to investigate the role of this protein in UC pathogenesis.

[Communications Biology] Researchers demonstrated that Claudin-2 was functionally required for colorectal cancer liver metastasis and that Claudin-2 expression in primary colorectal cancers was associated with poor overall and liver metastasis-free survival.